MapLight Therapeutics, Inc.
Financials
Valuation Metrics
MapLight Therapeutics, Inc.'s Market Cap is $480M. At end of 2025 it was $728M. Ranked #2811 of 3,121 in US market (top 90%), #1235 of 1,463 on NASDAQ (top 84%), #227 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 85%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $480M | US#2,811/3,121 Sec#227/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-230M | US—/3,121 Sec—/266 |
| Total Assets | $368M | US#2,870/3,121 Sec#197/266 |
| Net Assets | $348M | US#2,456/3,121 Sec#149/266 |
| Employees | 133 | US#2,577/3,121 Sec#158/266 |
| Value | ||
| P/B | 1.38x | US#772/3,121 Sec#29/266 |
| FCF Yield | -36.45% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -65.99% | US#2,740/3,121 Sec#181/266 |
| ROA | -62.39% | US#3,022/3,121 Sec#231/266 |
| Financial Health | ||
| Debt Ratio | 5.76% | US#47/3,121 Sec#19/266 |
| Total Debt | $2M | US#2,965/3,121 Sec#237/266 |
| FCF | $-175M | US#2,753/3,121 Sec#195/266 |
| Cash | $72M | US#2,416/3,121 Sec#202/266 |
| Current Ratio | 16.52x | US#148/3,121 Sec#40/266 |
| Performance | ||
| 1M Return | -4.23% | US#1,589/3,121 Sec#135/266 |
| From 52W High | -72.00% | US#3,031/3,121 Sec#246/266 |
| 1Y MDD | -75.13% | US#3,021/3,121 Sec#247/266 |
| Trading | ||
| Volume | 479,158 shares | US#2,049/3,121 Sec#216/266 |
| Trading Value | $5M | US#2,628/3,121 Sec#218/266 |
| Per Share | ||
| EPS | $-5.42 | US—/3,121 Sec—/266 |
| BPS | $8.21 | US#1,984/3,121 Sec#85/266 |
Company Info
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.